Opus Genetics: Chardan Capital keeps Buy rating, raises PT to $9.

Thursday, Nov 13, 2025 8:50 am ET1min read
IRD--

Opus Genetics: Chardan Capital keeps Buy rating, raises PT to $9.

Opus Genetics: Chardan Capital keeps Buy rating, raises PT to $9.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet